Financial Performance - Revenue for Q3 2021 was CNY 515,621,379.06, an increase of 4.25% year-over-year[2] - Net profit attributable to shareholders for Q3 2021 reached CNY 730,276,669.25, up 51.03% compared to the same period last year[2] - Basic earnings per share for Q3 2021 was CNY 0.6413, reflecting a 53.53% increase year-over-year[2] - Total operating revenue for Q3 2021 was CNY 1,598,367,824.71, a decrease of 1.1% compared to CNY 1,616,043,271.26 in the same period last year[12] - Net profit for Q3 2021 reached CNY 1,685,006,682.16, an increase of 12.7% from CNY 1,495,297,503.52 in Q3 2020[13] - The company reported a basic earnings per share of CNY 1.4851, compared to CNY 1.2954 in the previous year[13] Assets and Liabilities - Total assets as of September 30, 2021, amounted to CNY 28,786,224,336.56, representing a 5.24% increase from the end of the previous year[3] - The total assets of the company reached CNY 28.79 billion, up from CNY 27.35 billion, indicating a growth of about 5.3% year-over-year[10] - The total current assets amounted to approximately CNY 6.60 billion, an increase from CNY 6.18 billion at the end of 2020, reflecting a growth of about 6.7%[9] - The total non-current assets amounted to CNY 22.19 billion, an increase from CNY 21.17 billion, indicating a growth of approximately 4.8%[10] - Total liabilities increased to CNY 3,907,028,328.42 from CNY 3,824,172,838.66, indicating a rise in financial obligations[12] - The total liabilities decreased slightly to CNY 6.60 billion from CNY 6.61 billion, showing a marginal decline of about 0.2%[10] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 198,529,731.86, down 44.58% compared to the previous year[2] - Cash flow from operating activities was CNY 1,604,350,466.82, down from CNY 1,770,622,307.05 in the same quarter last year[14] - Operating cash inflow for Q3 2021 was CNY 1,728,106,361.65, a decrease of 11.8% from CNY 1,960,626,969.04 in Q3 2020[15] - Net cash outflow from investing activities was CNY 687,175,389.90, compared to a net inflow of CNY 325,363,129.86 in the same period last year[15] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 1,635,416,302.06, down from CNY 2,719,334,540.60 at the end of Q3 2020[16] Investments and Equity - The company reported a significant increase in trading financial assets, which rose by 96.57% to CNY 2,555,523,962.09 compared to the end of the previous year[7] - The company’s total equity attributable to shareholders increased by 5.75% to CNY 24,696,353,098.17 compared to the end of the previous year[3] - The company reported an investment income of CNY 1,604,374,249.69, up from CNY 1,489,490,948.12, indicating improved returns from investments[12] - The company has an undistributed profit of CNY 15,721,972,223.56, which contributes to its retained earnings[20] - The capital reserve stands at CNY 3,965,134,083.29, indicating a strong capital structure[20] Research and Development - Research and development expenses decreased by 32.61% to CNY 34,226,399.40 compared to the previous period[7] - Research and development expenses decreased to CNY 34,226,399.40 from CNY 50,787,103.62, suggesting a reduction in investment in innovation[12] Financial Obligations - The company's short-term borrowings decreased to CNY 356.03 million from CNY 373.38 million, representing a decline of about 4.7%[10] - The non-current liabilities totaled CNY 2,440,137,483.58, showing a decrease of CNY 35,128,105.81 from the previous period[19] - The company has a total of CNY 1,384,035,355.08 in current liabilities, reflecting its short-term financial obligations[19] Audit and Compliance - The company has not undergone an audit for the third quarter report, which may affect the perception of its financial statements[21] - The company is implementing new leasing standards effective from January 1, 2021, which may impact future financial reporting[20]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,082,746,445.65, a decrease of 3.45% compared to ¥1,121,445,607.54 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥962,283,316.78, down 5.67% from ¥1,020,099,858.24 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,040,667,183.37, a slight decrease of 0.37% compared to ¥1,044,491,211.06 last year[12]. - The net cash flow from operating activities was ¥269,979,631.46, representing a decline of 19.74% from ¥336,388,321.86 in the same period last year[12]. - Basic earnings per share were ¥0.84, down 4.55% from ¥0.88 in the previous year[12]. - Diluted earnings per share were ¥0.81, a decrease of 3.57% compared to ¥0.84 last year[12]. - The weighted average return on net assets was 4.06%, down from 4.50% in the previous year, a decrease of 0.44%[12]. - The total profit amounted to 949.78 million yuan, down by 74.49 million yuan, which is a year-on-year decrease of 7.27%[20]. - Revenue from the pharmaceutical sector was ¥871,343,034.74, accounting for 80.48% of total revenue, down 10.91% from ¥977,998,133.85[38]. - The company reported a significant increase in technology service fees contributing to other business income[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥28,285,485,428.68, an increase of 3.41% from ¥27,353,457,083.87 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥23,940,426,826.19, up 2.52% from ¥23,353,020,520.01 at the end of the previous year[12]. - The asset-liability ratio stood at 14.71%[20]. - Cash and cash equivalents decreased by 40.85% to ¥1,481,159,887.51, accounting for 5.24% of total assets[42]. - Accounts receivable increased by 24.66% to ¥673,857,351.66, representing 2.38% of total assets[42]. - Inventory rose by 11.77% to ¥613,036,151.61, making up 2.17% of total assets[42]. - Long-term equity investments increased by 2.09% to ¥18,176,160,507.64, comprising 64.26% of total assets[42]. - Total liabilities reached CNY 4.16 billion, up from CNY 3.82 billion, indicating a growth of around 8.9%[91]. Research and Development - The company continues to leverage its "industry-university-research collaborative innovation mechanism" to enhance R&D investment, focusing on the development of new varieties and the secondary development of major products[22]. - The company is actively exploring and optimizing classic traditional Chinese medicine formulas and standards for medicinal materials[23]. - The company is conducting preclinical research on Bai Lian Shen granules, which are intended for adjuvant therapy in lung cancer[24]. - The company is in the process of confirming the process for the production of five new products, including the oral liquid for diabetes (XMFWG001), which has submitted application materials and is under review by the national bureau[24]. - The company is focusing on the development of Best-in-class and First-in-class drugs targeting significant clinical needs[22]. - The company is committed to improving the quality and efficiency of its pharmaceutical products through continuous R&D efforts[22]. Investments - Investment income from Guangfa Securities for the period was 1.06 billion yuan, an increase of 55.93 million yuan, or 5.55% year-on-year[20]. - The company actively invests in various funds, including a 200 million yuan contribution to the Aodong Pharmaceutical Fund, accounting for 40% of the total fund[21]. - The company holds a 17.5752% stake in GF Securities, which reported a net profit of CNY 6,476,893,317.32, indicating strong performance in the securities brokerage sector[49]. - The investment in the fund "Guangfa Core Selected Mixed" generated a profit of CNY 323,871.23 during the reporting period[47]. Corporate Governance - The annual shareholders' meeting had a participation rate of 34.93%, reflecting investor engagement in corporate governance[52]. - The company does not plan to distribute cash dividends or issue new shares from capital reserves for the half-year period[53]. - The employee stock ownership plan was established in 2016, with 19,809,743 shares transferred to the plan's account[54]. - The employee stock ownership plan holds a total of 2,575.27 million shares, with 86.08% held by employees[55]. - The chairman, Li Xiulin, holds 182.00 million shares, representing 7.07% of the total stock ownership plan[55]. Environmental Compliance - The company has reported a total COD discharge of 1.62 tons, which is below the approved discharge limit of 2.437 tons[59]. - The company has implemented online monitoring equipment to ensure compliance with environmental discharge standards[61]. - There were no administrative penalties related to environmental issues during the reporting period[63]. - The company actively integrates ecological and environmental protection requirements into its development strategy[63]. Financial Reporting - The half-year financial report was not audited, indicating a potential area for future scrutiny[65]. - The financial statements are prepared in accordance with the relevant accounting standards and reflect the company's financial status accurately[122]. - The company has implemented specific accounting policies based on its operational characteristics, ensuring compliance with accounting standards[120]. Share Capital and Dividends - The company completed a share repurchase plan, acquiring 24,220,987 shares, which is 2.08% of the total share capital as of March 31, 2021[74]. - The maximum purchase price for the repurchased shares was set at RMB 20.00 per share, with actual prices ranging from RMB 15.05 to RMB 18.00 per share[75]. - The total amount spent on the share repurchase was RMB 400,032,878.38, including transaction fees[75]. - The company plans to use repurchased shares for the conversion of issued convertible bonds, with a deadline for implementation within 12 months from the approval date[74]. Market Strategy - The company aims to adjust its product structure and marketing strategies to mitigate the adverse effects of potential regional COVID-19 outbreaks on sales[51]. - The company plans to enhance its product market competitiveness and core capabilities in response to regulatory changes in the pharmaceutical industry[50].

吉林敖东药业集团股份有限公司 2021 年第一季度报告全文 吉林敖东药业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 吉林敖东药业集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 1 吉林敖东药业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | |-----------------------------------------------------------|-------------------|-------------------|------------------------- ...

Financial Performance - The company's operating revenue for 2020 was ¥2,251,650,950.38, a decrease of 27.09% compared to ¥3,088,379,591.97 in 2019[9] - The net profit attributable to shareholders for 2020 was ¥1,708,876,052.37, an increase of 21.75% from ¥1,403,640,313.56 in 2019[9] - The net profit after deducting non-recurring gains and losses was ¥1,647,506,111.99, up 28.97% from ¥1,277,462,446.54 in 2019[9] - The basic earnings per share for 2020 was ¥1.4753, representing a growth of 22.23% compared to ¥1.2070 in 2019[9] - The total assets at the end of 2020 were ¥27,353,457,083.87, an increase of 6.02% from ¥25,800,904,916.27 at the end of 2019[9] - The net assets attributable to shareholders at the end of 2020 were ¥23,353,020,520.01, a rise of 4.96% from ¥22,249,498,565.07 at the end of 2019[9] - The net cash flow from operating activities for 2020 was ¥390,408,759.72, an increase of 2.89% from ¥379,456,901.57 in 2019[9] - The diluted earnings per share for 2020 was ¥1.4298, which is a 20.92% increase from ¥1.1824 in 2019[9] - The weighted average return on equity for 2020 was 7.48%, up from 6.50% in 2019[9] Revenue Breakdown - In 2020, the company reported total revenue of approximately CNY 2.25 billion, with quarterly revenues of CNY 468.29 million, CNY 653.16 million, CNY 494.60 million, and CNY 635.61 million respectively[12] - The net profit attributable to shareholders for the year was approximately CNY 1.70 billion, with quarterly net profits of CNY 328.32 million, CNY 691.78 million, CNY 483.53 million, and CNY 205.25 million respectively[12] - The company's total assets at the end of 2020 were CNY 27.35 billion, and net assets were CNY 23.53 billion, maintaining a consistent profit tax exceeding CNY 1 billion for several years[15] - Pharmaceutical revenue accounted for CNY 1,905,975,932.48, representing 84.65% of total revenue, down 32.51% from CNY 2,823,902,969.94 in 2019[39] - The revenue from chain pharmacy wholesale and retail increased by 85.76% to CNY 141,502,333.68, compared to CNY 76,174,849.32 in 2019[39] Investment and R&D - Increased R&D investment to strengthen core capabilities and support high-quality development in the pharmaceutical industry[25] - New product development includes clinical research on Bai Lian Shen granules for lung cancer treatment and other traditional Chinese medicine formulations[26][27] - The company is pursuing a "dual-wheel drive" growth model combining industry and finance to support sustainable development[21] - The company is actively enhancing its industry layout and core competitiveness in the pharmaceutical sector through accelerated project construction[36] - The company is committed to enhancing its research capabilities across multiple areas, including clinical evidence-based medicine and quality improvement[28] Market Strategy and Expansion - The company is actively expanding into health food, agriculture, and other sectors, while continuing to develop its core pharmaceutical business[14] - The company is expanding its marketing strategy by integrating resources and enhancing product competitiveness based on consumer demand[31] - The company plans to focus on core traditional Chinese medicine products and adjust its product structure and channel coverage in response to national healthcare reforms and procurement policies[90] - The company aims to implement a sales policy of "leading varieties and multiple varieties progressing together" to enhance market competitiveness[86] Corporate Governance and Compliance - The company has maintained a good integrity status with no significant legal judgments or debts overdue during the reporting period[109] - The company has not faced any major litigation or arbitration matters during the reporting period[109] - The company has implemented strict insider information management to prevent leaks and ensure compliance with regulations[182] - The company has established an independent financial accounting department and management system, conducting financial decisions independently and maintaining separate bank accounts[185] Social Responsibility and Environmental Compliance - The company has a focus on social responsibility, integrating it into its strategic development[121] - The company has achieved compliance with environmental protection standards, with no exceedances reported during the reporting period[126] - The company has received environmental protection administrative permits for all its subsidiaries, adhering to local and national regulations[126] - The company has implemented various employee benefits to foster a learning organization and improve overall employee quality[38] Shareholder Returns - The company plans to distribute a cash dividend of ¥2 per 10 shares to all shareholders[2] - The total cash dividend (including other methods) for 2020 was 527,796,662.91 CNY, which accounted for 30.89% of the net profit attributable to shareholders[99] - The cash dividend policy was confirmed to comply with the company's articles of association and shareholder resolutions[96] - The company has not issued any bonus shares in the recent three years, maintaining a consistent cash dividend policy[98] Employee Engagement and Structure - The total number of employees in the company is 4,462, with 34 in the parent company and 4,428 in major subsidiaries[173] - The employee composition includes 1,938 production personnel, 1,414 sales personnel, 401 technical personnel, 141 financial personnel, and 568 administrative personnel[174] - The company has established a comprehensive training system to enhance employee skills and competitiveness[175] - The employee stock ownership plan is a significant part of the company's shareholding structure, indicating strong employee engagement[150]

吉林敖东药业集团股份有限公司 2020 年第三季度报告全文 吉林敖东药业集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 吉林敖东药业集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 2 吉林敖东药业集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------|---------------------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,121,445,607.54, a decrease of 31.73% compared to CNY 1,642,579,794.10 in the same period last year[9]. - Net profit attributable to shareholders was CNY 1,020,099,858.24, an increase of 16.97% from CNY 872,113,433.98 year-on-year[10]. - The net profit after deducting non-recurring gains and losses reached CNY 1,044,491,211.06, reflecting a growth of 26.94% compared to CNY 822,844,295.99 in the previous year[10]. - The net cash flow from operating activities was CNY 336,388,321.86, showing a significant increase of 190.08% from CNY 115,962,509.53 in the same period last year[10]. - Basic earnings per share were CNY 0.88, up 17.33% from CNY 0.75 in the previous year[10]. - Total profit increased to CNY 10,242.79 million, an increase of CNY 1,072.35 million or 11.69% year-on-year[23]. - The company reported a total profit of CNY 1,024,278,617.81, up from CNY 917,043,908.38, indicating a growth of 11.7%[117]. - The total comprehensive income for the first half of 2020 was approximately CNY 1.19 billion, compared to CNY 841.18 million in the same period of 2019, representing an increase of about 41%[120]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 27,064,353,195.25, an increase of 4.90% from CNY 25,800,904,916.27 at the end of the previous year[10]. - The company's total assets increased to approximately 27.06 billion yuan from 25.80 billion yuan at the end of the previous year[111]. - Total liabilities reached CNY 3,964,628,585.52, up from CNY 3,356,209,814.31, reflecting a growth of approximately 18.1%[112]. - The company's equity attributable to shareholders increased to CNY 22,909,857,193.45 from CNY 22,249,498,565.07, a rise of about 3.0%[112]. - The total liabilities to equity ratio was approximately 0.17, indicating a stable leverage position[112]. Investment and Capital Management - The company plans to invest CNY 2.2 billion in securities management to enhance asset efficiency and returns[26]. - The company completed a significant equity investment in Guangfa Securities Co., Ltd. amounting to ¥195,445,670.77, acquiring a 0.34% stake[41]. - The company has allocated CNY 509.75 million of unutilized raised funds for working capital, optimizing its industrial layout[32]. - The company has invested CNY 2,084,200,000.00 in bonds, with a sale amount of CNY 2,054,282,370.35 during the reporting period[45]. - The company used 99,600 million yuan of the raised funds to increase capital in its subsidiaries to enhance profitability[95]. Research and Development - Research and development expenses decreased by 46.54% to CNY 45,545,535.47 from CNY 85,196,186.50 in the previous year, mainly due to reduced R&D spending by subsidiaries[33]. - The company plans to increase investment in new product research and development to mitigate the impact of national medical reform policies[52]. Market and Operational Challenges - The company faced operational challenges in the first half of 2020 due to the COVID-19 pandemic, impacting production and logistics[22]. - The company experienced a decrease in revenue across all major regions, with the Northeast region declining by 28.30% to CNY 309,859,964.06[34]. Shareholder and Equity Management - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company has implemented an employee stock ownership plan, with 19,809,743 shares transferred to the plan's account[58]. - The total number of ordinary shareholders at the end of the reporting period was 93,172[80]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.65% of the shares, totaling 309,940,049 shares[80]. Environmental and Social Responsibility - The company has invested over 60 million yuan in wastewater treatment facilities over the past three years, with a maximum daily treatment capacity of 8,000 tons[68]. - The company is committed to poverty alleviation efforts, focusing on precise identification and management of poverty alleviation initiatives[69]. - A total of CNY 160.42 million was allocated for poverty alleviation efforts, benefiting 670 registered impoverished individuals[72]. Financial Reporting and Compliance - The company's financial statements are prepared based on the going concern principle and comply with relevant accounting standards[138]. - The company has no significant issues regarding its ability to continue as a going concern for the next 12 months[139]. - The company’s long-term credit rating remains at AA+ with a stable outlook, as confirmed by Pengyuan Credit Rating Co., Ltd. in multiple reports from 2017 to 2020[99][100].

吉林敖东药业集团股份有限公司 2020 年第一季度报告全文 吉林敖东药业集团股份有限公司 2020 年第一季度报告 2020 年 04 月 吉林敖东药业集团股份有限公司 2020 年第一季度报告全文 1 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 吉林敖东药业集团股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------------|-------------------|-------|-------------------|----------- ...

Financial Performance - The company's operating revenue for 2019 was ¥3,088,379,591.97, a decrease of 7.09% compared to ¥3,324,078,265.78 in 2018[8]. - Net profit attributable to shareholders for 2019 was ¥1,403,640,313.56, representing a 50.09% increase from ¥935,187,893.18 in 2018[8]. - The net profit after deducting non-recurring gains and losses was ¥1,277,462,446.54, up 45.43% from ¥878,430,261.44 in the previous year[8]. - Basic earnings per share for 2019 were ¥1.2070, an increase of 50.07% compared to ¥0.8043 in 2018[8]. - The total operating revenue for the company in 2019 was RMB 3,088,379,591.97, representing a decrease of 7.09% compared to RMB 3,324,078,265.78 in 2018[34]. - The net profit attributable to shareholders was CNY 140,364.03 million, an increase of CNY 46,845.24 million or 50.09% year-on-year[22]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2019, representing a year-over-year increase of 10%[147]. - The net profit for the year was 300 million RMB, which is a 15% increase compared to the previous year[147]. Assets and Liabilities - Total assets at the end of 2019 were ¥25,800,904,916.27, a 4.63% increase from ¥24,658,542,292.54 at the end of 2018[8]. - Net assets attributable to shareholders at the end of 2019 were ¥22,249,498,565.07, reflecting a 5.81% increase from ¥21,028,405,792.95 in 2018[8]. - The total assets of the company at the end of 2019 were ¥25.80 billion, with net assets of ¥22.44 billion[15]. - The asset-liability ratio stands at 13.01%, indicating a strong financial position[22]. - The company's total assets-liabilities ratio as of December 31, 2019, was 13.01%, a decrease from 13.85% in 2018, indicating strong debt repayment capability[181]. Cash Flow - The company reported a net cash flow from operating activities of ¥379,456,901.57, an increase of 9.15% from ¥347,635,221.58 in 2018[8]. - The total cash inflow from operating activities in 2019 was CNY 3,521,658,072.52, a decrease of 4.53% compared to 2018[5]. - The net cash flow from investment activities turned positive at CNY 157,887,970.79, a 109.00% increase compared to the previous year[5]. - Cash and cash equivalents increased by CNY 275,722,053.55, a decrease of 62.04% year-on-year[5]. Investments and Acquisitions - The company invested CNY 8,244.17 million in the automation production line project, which has commenced production[25]. - The company completed the acquisition of Auscon Biopharmaceuticals with an investment of CNY 12 million, holding a 1.39% stake[52]. - The company invested CNY 152.47 million in various self-built projects, with a cumulative actual investment of CNY 259.17 million by the end of the reporting period[53]. - The company plans to invest 100 million yuan in R&D for new technologies over the next two years[140]. Research and Development - R&D efforts include the development of new drugs and classic formulas, with ongoing projects for various treatments including pancreatic and lung cancer[26]. - Research and development expenses rose by 62.52% to 142,897,914.24 yuan, primarily due to increased product development spending by subsidiaries[43]. - The company aims to enhance its core competitiveness through continuous investment in talent development and training programs[32]. Market and Sales - The pharmaceutical segment generated RMB 2,897,045,013.07, accounting for 93.80% of total revenue, with an 8.61% decline from RMB 3,170,006,912.71 in the previous year[34]. - The food segment revenue increased by 31.76% to RMB 131,045,206.69, compared to RMB 99,460,290.59 in 2018[34]. - The total sales volume for the pharmaceutical sector decreased by 1.86% to 106,696,920 boxes in 2019 compared to 2018[36]. - The production volume for food increased by 57.70% to 11,382,853 boxes in 2019, driven by the growth of the subsidiary Jilin Aodong Health Technology Co., Ltd.[36]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥2 per 10 shares to all shareholders[2]. - The total cash dividend amount for 2019 is 232,607,090.80 CNY, which represents 16.57% of the net profit attributable to ordinary shareholders[83]. - The cash dividend total for 2019 represents 100% of the total distributable profits[85]. Corporate Governance - The company has established a robust investor relations management system to enhance communication with investors[157]. - The company operates independently from its controlling shareholder in business, personnel, assets, institutions, and finance[159]. - The company’s board of directors is responsible for establishing and maintaining effective internal controls as per regulatory requirements[172]. Environmental and Social Responsibility - The company has invested over 60 million RMB in wastewater treatment facilities over the past three years, achieving a maximum daily treatment capacity of 8,000 tons[110]. - The company has actively integrated ecological and environmental protection requirements into its development strategy and governance processes[110]. - A total of 28 million yuan was allocated for poverty alleviation efforts, helping 225 registered impoverished individuals to escape poverty[106]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year[136]. - The company has set a revenue guidance of 1.8 billion RMB for the fiscal year 2020, projecting a growth of 20%[147]. - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels[147].

Financial Performance - Operating revenue decreased by 12.27% to CNY 715,984,530.35 compared to the same period last year[3] - Net profit attributable to shareholders decreased slightly by 0.02% to CNY 287,593,890.59 compared to the same period last year[3] - Net profit after deducting non-recurring gains and losses increased by 4.20% to CNY 280,901,534.93 compared to the same period last year[3] - Basic earnings per share decreased by 0.04% to CNY 0.2473 compared to the same period last year[3] - Diluted earnings per share increased by 0.04% to CNY 0.2465 compared to the same period last year[3] - The weighted average return on equity was 1.33%, a decrease of 0.05% compared to the same period last year[3] - The total comprehensive income for the third quarter was CNY 288,216,002.04, down from CNY 350,046,111.19 in the same period last year, indicating a decline of 17.7%[26] - The net profit for the third quarter was CNY 284,540,757.67, slightly up from CNY 282,995,744.96 in the same period last year, reflecting a growth of 0.5%[26] - The total profit for the third quarter was CNY 301,054,120.13, slightly up from CNY 299,502,704.47 in the previous year, indicating a growth of 0.5%[26] Assets and Liabilities - Total assets increased by 4.14% to CNY 25,679,514,163.64 compared to the end of the previous year[3] - Total liabilities decreased to CNY 3,370,375,690.25 from CNY 3,414,160,963.84, showing a reduction of about 1.28%[19] - The company's total current assets reached CNY 6,152,836,061.00, up from CNY 5,801,997,576.69 in December 2018, indicating an increase of about 6.05%[17] - The total equity of the company increased to CNY 20,910,565,731.18 from CNY 20,104,377,556.79, reflecting a growth of approximately 4.0%[24] - The company's total liabilities reached CNY 2,084,332,917.57, compared to CNY 1,991,597,896.24, representing an increase of about 4.66%[22] - The total owner's equity reached CNY 22,309,138,473.39, up from CNY 21,244,381,328.70, indicating an increase of approximately 4.99%[19] Cash Flow - Cash flow from operating activities decreased by 40.22% to CNY 188,502,033.41 compared to the same period last year[3] - The ending balance of cash and cash equivalents was 1,896,676,761.32, down from 2,024,209,120.45 in the previous period, reflecting a decrease of about 6.3%[37] - Cash inflow from operating activities totaled 2,579,117,457.22, down from 2,676,860,371.64, marking a decline of approximately 3.6%[36] - Operating cash flow for the period was 188,502,033.41, a decrease from 315,302,865.68 in the previous period, indicating a decline of approximately 40.2%[36] Research and Development - The company's R&D expenses increased by 83.17% year-on-year to ¥110,694,497.61, primarily due to increased product development expenditures by subsidiaries[9] - Research and development expenses rose significantly to CNY 40,100,622.46, compared to CNY 12,458,801.49, marking an increase of about 221.5%[25] - The research and development expenses increased to CNY 110,694,497.61 from CNY 60,432,758.81 in the previous year, reflecting a significant increase of 83.2%[29] Investment Income - Investment income rose by 34.95% year-on-year to ¥941,623,783.47, attributed to higher returns from investments in Guangfa Securities Co., Ltd.[9] - The company reported a net investment income increase to CNY 247,591,555.11, up from CNY 216,482,214.48, which is an increase of approximately 14.4%[25] - The company’s investment income from joint ventures and associates increased to ¥933,216,241.86 from ¥669,764,566.38, reflecting a growth of about 39.4%[30] Other Comprehensive Income - The company's other comprehensive income after tax increased by 176.33% to ¥135,130,886.22, driven by increased other comprehensive income from Guangfa Securities[8] - Other comprehensive income after tax for the current period was ¥135,130,886.22, a recovery from a loss of ¥177,026,979.30 in the previous period[30] - The company reported a decrease in other comprehensive income by CNY 135,967,126.33 compared to the previous period[48] Shareholder Information - The company extended the employee stock ownership plan by 18 months, now set to expire on December 8, 2020[13] - The company committed to not trading or transferring shares for 36 months post the stock reform, with a maximum annual reduction of 2% of total shares at a minimum price of 7.5 yuan per share[14] - The company’s major shareholder's restricted shares will be fully tradable by August 4, 2020[14] Financial Standards - The company has implemented new financial instrument standards effective from January 1, 2019, impacting the classification and measurement of financial instruments[44] - The company implemented new financial instrument standards starting January 1, 2019, affecting the classification and measurement of financial instruments[49]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,642,579,794.10, representing a 3.93% increase compared to CNY 1,580,502,489.40 in the same period last year[9]. - Net profit attributable to shareholders was CNY 872,113,433.98, a 43.38% increase from CNY 608,241,663.21 year-on-year[10]. - The net profit after deducting non-recurring gains and losses was CNY 822,844,295.99, up 35.37% from CNY 607,836,792.61 in the previous year[10]. - Basic earnings per share increased to CNY 0.75, a rise of 44.23% compared to CNY 0.52 in the same period last year[10]. - The gross profit margin was 70.87%, a decrease of 1.17% compared to the same period last year[30]. - The pharmaceutical segment generated revenue of RMB 1,553,790,258.75, with a gross margin of 74.11%[30]. - The company reported a total of CNY 1,109,616,361.43 in securities investments, with a year-end book value of CNY 1,106,543,443.25[38]. - The company reported a total comprehensive income of CNY -238,858,399.35 for the current period, with a profit distribution of CNY -348,830,988.60[115]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 25,452,780,371.52, reflecting a 3.22% increase from CNY 24,658,542,292.54 at the end of the previous year[10]. - The net assets attributable to shareholders reached CNY 21,812,001,031.40, which is a 3.73% increase from CNY 21,028,405,792.95 at the end of the previous year[10]. - The company's total liabilities were CNY 3,430,406,105.67, slightly up from CNY 3,414,160,963.84, showing a marginal increase of about 0.5%[93]. - The total liabilities to equity ratio was approximately 15.7%, indicating a stable leverage position for the company[93]. - The company's long-term equity investments increased to CNY 15,966,996,324.35, representing 62.73% of total assets[32]. Cash Flow - The net cash flow from operating activities was CNY 115,962,509.53, down 38.44% from CNY 188,370,631.11 in the same period last year[10]. - The company’s operating cash flow decreased by 38.44% to 115.9625 million RMB due to increased operating expenses[29]. - The cash inflow from investment activities reached ¥2,091,472,158.13, significantly up from ¥413,566,231.73 in the first half of 2018[106]. - The cash and cash equivalents at the end of the first half of 2019 amounted to 1,939,800,326.10, compared to 1,427,518,742.77 at the end of the first half of 2018[105]. Investments and R&D - Research and development investment increased by 24.19% to 85.1962 million RMB compared to the previous year[29]. - The company has invested 100 million RMB in research and development for innovative technologies to improve production efficiency[128]. - The company reported investment income of CNY 694,032,228.36, which is an increase from CNY 481,277,265.08 in the first half of 2018[99]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company is focusing on innovation and quality improvement to adapt to the evolving pharmaceutical industry landscape[20]. - The company has established a dual-driven growth model of "industry + finance" to support its development strategy[19]. - The company plans to enhance product quality and service levels while accelerating new product development to adapt to ongoing pharmaceutical policy changes[43]. Market and Competition - The company is expanding its market presence by entering two new regions, which is anticipated to increase market share by 5%[128]. - A strategic acquisition of a smaller competitor was completed, valued at 500 million RMB, aimed at enhancing product offerings and market reach[128]. Shareholder Information - The total number of shares held under the employee stock ownership plan is 25,752,666 shares, with 86.08% held by employees and the remaining by directors and supervisors[53]. - The company plans to increase its stake in Jilin Aodong Pharmaceutical Group by at least 5% within 12 months after the implementation of the share reform plan, aiming for a total holding of 25% within 36 months[48]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.65% of shares, totaling 309,940,049 shares[74]. Environmental and Social Responsibility - The company actively participates in precision poverty alleviation efforts, focusing on targeted support and resource allocation[66]. - The company signed a poverty alleviation cooperation agreement for black bean planting with the Xiaowazi Village, contributing to local economic development[67]. - The company has implemented effective pollution prevention measures, ensuring that emissions meet environmental standards[64]. Financial Management - The company has a total bank credit line of 3.1 billion CNY, with an unused portion of 3.1 billion CNY as of June 30, 2019[89]. - The company maintained a 100% loan repayment rate and interest payment rate during the reporting period[87]. - The company has adhered to the commitments outlined in the convertible bond prospectus without harming investor interests[90]. Risk Factors - The company is facing risks from increasing environmental regulations, which may lead to higher operational costs and potential production disruptions[44]. - The company’s product "Injection of Ribonucleic Acid II" has been included in the first batch of key monitored drug lists, which may adversely affect the company's performance[45].